Batu Biologics appoints Solana Beach resident as board chairman
Batu Biologics, a San Diego biotechnology company dedicated to the development of ValloVax, its cancer angiogenesis-targeting immunotherapeutic product, announced today the appointment of Dr. Alan Lewis of Solana Beach as chairman of its board of directors.
“I look forward to working with the team on continuing this path of accelerated success, which will hopefully bring a new class of weapons in the fight against cancer,” said Samuel Wagner, president and CEO of Batu Biologics.
“We are enthusiastic to have the opportunity to work with Dr. Lewis in his new capacity as chairman of the board. Given the recent filing of an IND (investigational new drug application) with the FDA to initiate a dose-escalating Phase I/II clinical trial in lung cancer, we believe that having a chairman with the industry experience of Dr. Lewis will strategically position Batu Biologics for entry into partnerships and collaborations with others in the field.”
Lewis serves on the board of BioMarin and a number of private biotechnology companies. His most recent position was CEO of Medistem Inc., where he worked with Batu Biologics co-founder Dr. Thomas Ichim to obtain FDA clearance for a cell-based therapy, which resulted in a $26 million sale of Medistem to Intrexon, an NYSE-traded company.